Zentalis Pharmaceuticals Raises $165 Million in Expanded IPO

Zentalis Pharmaceuticals Inc., a clinical-stage cancer treatment developer, raised about $165 million in its initial public offering, the second company to go public in the U.S. since Covid-19 was declared a pandemic.